Adult & Pediatric Urology
Welcome,         Profile    Billing    Logout  
 13 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trainer, Andrew
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Recruiting
N/A
500
US
Data collection
Urotronic Inc.
Benign Prostatic Hyperplasia
03/27
03/27
McCrery, Rebecca
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Recruiting
3
14000
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
03/29
03/29
OASIS, NCT03596671: BlueWind RENOVA iStim™ System for the Treatment of OAB

Recruiting
N/A
200
Europe, US
RENOVA iStim™ System
BlueWind Medical
Treatment of Patients Suffering From Overactive Bladder (OAB)
10/22
01/25
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study

Recruiting
N/A
130
Europe, US
Axonics SNM System (Model 4101)
Axonics, Inc.
Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
03/25
06/26
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Recruiting
N/A
150
US
Revi System Treatment, Revi System - Delayed Activation
BlueWind Medical
Urinary Urge Incontinence
05/25
05/27
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes

Completed
N/A
47
US
eCoin Peripheral Neurostimulator System
Valencia Technologies Corporation
Urge Incontinence
04/24
05/24
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Recruiting
N/A
200
US
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Uro Medical Corporation
Urinary Incontinence, Urge
10/25
10/25
Meays, Megan
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
Nelson, Amy
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study

Recruiting
N/A
130
Europe, US
Axonics SNM System (Model 4101)
Axonics, Inc.
Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
03/25
06/26
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Recruiting
N/A
150
US
Revi System Treatment, Revi System - Delayed Activation
BlueWind Medical
Urinary Urge Incontinence
05/25
05/27
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Recruiting
N/A
500
US
Data collection
Urotronic Inc.
Benign Prostatic Hyperplasia
03/27
03/27
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes

Completed
N/A
47
US
eCoin Peripheral Neurostimulator System
Valencia Technologies Corporation
Urge Incontinence
04/24
05/24
PROGECT, NCT02302742: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Recruiting
N/A
1500
US
University of Kansas Medical Center
Breast Cancer, Hereditary Breast and Ovarian Cancer
12/24
12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift

Recruiting
N/A
206
Europe, US
iTind, UroLift
Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
12/25
12/30
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Recruiting
N/A
200
US
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Uro Medical Corporation
Urinary Incontinence, Urge
10/25
10/25
Kramolowsky, Eugene
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
Howard, Amber
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
OASIS, NCT03596671: BlueWind RENOVA iStim™ System for the Treatment of OAB

Recruiting
N/A
200
Europe, US
RENOVA iStim™ System
BlueWind Medical
Treatment of Patients Suffering From Overactive Bladder (OAB)
10/22
01/25
Quigley, Brittany
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
Amarasekera, Channa
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift

Recruiting
N/A
206
Europe, US
iTind, UroLift
Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
12/25
12/30

Download Options